CNC Q1 2026: Beat-and-Raise — HBR 87.3%, EPS $3.37, FY Guide Lifted to $3.40

Centene reported a Q1 2026 consolidated health benefits ratio of 87.3% — 270bps below the 90% bear-case threshold and ~400bps better than Q4 2025's 94.3%. Adjusted EPS of $3.37 in a single quarter already exceeds the original full-year FY2026 guide of >=$3.00. Management raised the FY guide to >=$3.40 less than 90 days after the original guide and added $1B to the revenue range. $4.4B in operating cash flow funded a $1B senior-note paydown, improving debt-to-cap by 330bps to 43.2%. The stock rerated +42% from $34.89 on March 17 to $49.56 post-earnings. The March 17 baseline framed Q1 as the central credibility test. It cleared with margin.

The Numbers

The Guidance Pivot

Less than 90 days after the original FY2026 guide, management raised adjusted EPS from >=$3.00 to >=$3.40 — a +13% revision — and added $1B to the revenue range (now ~$171-175B). This is the opposite of the FY2025 dynamic, where management withdrew guidance entirely after the $1.8B ACA risk adjustment shortfall. Pre-guidance street consensus for FY2026 was ~$2.50; even the new >=$3.40 figure is well above that. Drivers of the raise:

• SG&A ratio: tightened 10bps in the FY guide; Q1 actual 7.6% vs Q1 2025 7.9%
• Investment income: +$50M to FY guidance
• Medicaid composite rate yield: reaffirmed ~4.5%
• Marketplace pretax margin: guided ~3% (down from ~4% original) as a "prudent posture" pending the June Wakely report — but the data-implied range "wraps around" the original 4% target with full risk-adjustment receivable

Balance Sheet: $1B Debt Paydown via PDP Receivable Sale

$4.4B Q1 operating cash flow is the single most consequential balance sheet data point. It directly resolves the Stress Scanner's baseline concern of "negative cash flow risk in Q4 2025 on operating losses." Management used $1B of PDP receivable monetization proceeds to repurchase senior notes, dropping debt-to-cap 330bps to 43.2%. $437M cash for general corporate use. Refinancing of upcoming 2027/2028 maturities discussed as routine. Medical claims liability $20.6B; days claims payable up 2 days to 48 (PDP sloping will drive that down later in year).

The disciplined choice — debt paydown rather than incremental buyback at peak uncertainty — is itself a credibility signal. The Stress Scanner debate over "buybacks during operating losses as disciplined or reckless" loses urgency when cash flow is $4.4B positive and the company actively deleverages.

Marketplace: Controlled Contraction at 3.58M

ACA Marketplace ended Q1 at 3.58M members, down from 5.5M at year-end 2025 and right in line with prior commentary of ~3.5M by Q1 2026. Year-end target reaffirmed at "a little over 3M." The Wakely industry-wide Q1 data submission corroborated the market-wide Silver-to-Bronze mix shift and attributed higher Silver utilization to acuity, not adverse selection. The contraction is controlled rather than spiraling.

The new tension: Q1 booked the Marketplace risk adjustment as a receivable, but management is NOT booking the full data-implied receivable in guidance. CFO Drew Asher: "by year-end to be in that slight receivable position. So that's sort of the difference when you're evaluating that table in the Q." This is conservative posture pending the June Wakely report — but the gap between Q1 actual and FY assumption creates true-up risk in either direction. The June Wakely report is now the single most important Marketplace data point of FY2026.

Forecast Markets: One Resolved, Six Active

The Q1 HBR market is the only resolution of the cycle. The bearish 0.42 ensemble took a meaningful Brier hit (0.34) against the 87.3% outcome — a teaching moment on how aggressively MCO HBR can mean-revert when management gets prior-year reset year accounting and member-mix re-pricing right simultaneously. The EPS market is functionally de-risked but cannot resolve until Feb 2027 reporting.

Signal Changes: Two Lenses De-Escalating

• Gravy Gauge — REVENUE_DURABILITY: FRAGILE held, with de-escalation pending. Q1 demonstrates revenue per member economics improving across all three segments and ACA contraction lands inside expected band. Likely upgrade to CONDITIONAL after Q2-Q3 confirms it isn't entirely seasonal.
• Stress Scanner — FUNDING_FRAGILITY: ELEVATED held, with de-escalation pending. $4.4B Q1 cash flow + $1B debt paydown materially reduces fragility. Likely downgrade to STRETCHED after Q2 confirmation of capital allocation discipline.
• Stress Scanner — CAPITAL_DEPLOYMENT: STRAINED held, de-escalation pending. PDP receivable monetization to retire debt rather than incremental buyback supports the shift, but held pending Q2 capital allocation visibility.
• Regulatory Reader — REGULATORY_EXPOSURE: EXISTENTIAL unchanged. OBBBA, ACA subsidy expiration, and securities litigation overhang all persist. CMS rate-certification guidance is a marginal positive, not a structural change to the addressable market.
• Moat Mapper / Insider Investigator: Unchanged. No state contract events, no new Form 4 transactions, litigation status quo.

Next Catalysts

• June Wakely report — primary Marketplace data point; could push Marketplace pretax margin guide back toward original ~4% if slight receivable confirmed
• Q2 2026 earnings (~July) — sustainability test for Q1 Medicaid HBR absent flu/weather tailwind; Marketplace membership floor confirmation
• CMS final OBBBA implementation guidance (by Q3 2026) — severity sets 2027 Medicaid baseline
• 2027 MA bid filings (mid-2026) — gates breakeven-by-2027 thesis; final 2027 rates remain below medical cost trend
• Medicaid rate certification cycle (back-half 2026) — state filings incorporating OB3 acuity dynamics determine 2027 starting point